Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of […]
Recent Content
- Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
- Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
- Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
- Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
- Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
- ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
- Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
- Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
- Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma